Funded Biotechnology Startups in Netherlands
The 50 most recent funded biotechnology rounds in the Netherlands span October 2021 through October 2025, with Amsterdam (Noord-Holland) accounting for the…
The 50 most recent funded biotechnology rounds in the Netherlands span October 2021 through October 2025, with Amsterdam (Noord-Holland) accounting for the largest cluster — companies including Leyden Labs, LUMICKS, and VectorY have all raised there. The single largest disclosed round is Merus's $300M in June 2025, followed by New Amsterdam Pharma's $235M in November 2022 and VectorY's $138M Series A in November 2023.
Series B activity has clustered from late 2024 into 2025: Citryll closed $90M in December 2024, Salvia BioElectronics $60M in May 2025, The Protein Brewery $35M in September 2025, and Revyve $28M the following day. Beyond Amsterdam, active nodes include Leiden (Anavo Therapeutics, In Ovo, BIMINI Biotech), Wageningen (Revyve, Hudson River Biotechnology, Micreos), and the Noord-Brabant corridor covering Eindhoven, Oss, and Breda. Several rounds carry undisclosed amounts, and a number are classified as Series Unknown, which limits stage-level analysis.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest disclosed funding rounds in this group?
Merus leads with $300M in June 2025, followed by New Amsterdam Pharma at $235M (November 2022) and VectorY at $138M Series A (November 2023). NorthSea Therapeutics ($80M Series C, December 2021) and Citryll ($90M Series B, December 2024) also rank among the top deals by disclosed size.
Which cities in the Netherlands have the most biotech funding activity?
Amsterdam (Noord-Holland) has the densest concentration, with roughly a dozen companies in this set including Leyden Labs, LUMICKS, VectorY, Scenic Biotech, and NLC. Leiden (Zuid-Holland) and the Noord-Brabant corridor — spanning Eindhoven, Oss, and Breda — are the next most represented, followed by Wageningen and Utrecht.
How active has Series B deal flow been in Dutch biotech recently?
Four Series B rounds closed between December 2024 and September 2025: Citryll ($90M), Salvia BioElectronics ($60M), The Protein Brewery ($35M), and Revyve ($28M). That concentration of mid-stage capital across a nine-month span is the most active Series B cluster in the dataset.
What early-stage activity is visible among Netherlands biotech startups?
Pre-seed and seed rounds appear across multiple cities. QurieGen (Nijmegen, $2M pre-seed, April 2025), BIMINI Biotech (Leiden, $3M seed, January 2025), and Alveron Pharma (Nijmegen, $5M seed, December 2024) are the most recent early-stage entries. Bionomic (Oegstgeest, $380K pre-seed, November 2024) is among the smallest disclosed rounds in the set.
How many rounds have undisclosed amounts or unknown stage labels?
At least eight companies — including Ace Pharmaceuticals, Hudson River Biotechnology, Batavia Biosciences, Qorium, and BioConnection — reported undisclosed amounts. A large share of rounds also carry a 'Series Unknown' label, which limits stage-based filtering but does not affect date or geographic analysis.
Which provinces outside Amsterdam see consistent biotech investment?
Gelderland hosts Revyve, Khondrion, QurieGen, Hudson River Biotechnology, and Micreos across Wageningen and Nijmegen. Noord-Brabant covers Salvia BioElectronics and Chromodynamics in Eindhoven, Citryll and RiboPro in Oss, and The Protein Brewery in Breda. Zuid-Holland adds activity in Leiden, Delft, Rotterdam, and Oegstgeest.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.